Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
DOCS vs VEEV vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Banks - Diversified
DOCS vs VEEV vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Banks - Diversified |
| Market Cap | $3.75B | $25.92B | $896.00B |
| Revenue (TTM) | $645M | $3.32B | $280.33B |
| Net Income (TTM) | $196M | $942M | $57.05B |
| Gross Margin | 89.1% | 75.0% | 60.0% |
| Operating Margin | 33.3% | 28.8% | 25.9% |
| Forward P/E | 14.0x | 17.6x | 14.4x |
| Total Debt | $10M | $96M | $942.38B |
| Cash & Equiv. | $219M | $1.42B | $343.34B |
DOCS vs VEEV vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | Jun 26 | Return |
|---|---|---|---|
| Doximity, Inc. (DOCS) | 100 | 34.4 | -65.6% |
| Veeva Systems Inc. (VEEV) | 100 | 51.3 | -48.7% |
| JPMorgan Chase & Co. (JPM) | 100 | 206.2 | +106.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DOCS vs VEEV vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DOCS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.75, Low D/E 1.1%, current ratio 6.09x
- PEG 0.27 vs VEEV's 0.97
- Lower P/E (14.0x vs 17.6x), PEG 0.27 vs 0.97
VEEV is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.69
- Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
- Beta 0.69, current ratio 4.89x
JPM is the clearest fit if your priority is long-term compounding.
- 465.8% 10Y total return vs VEEV's 367.2%
- 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
- +21.8% vs DOCS's -64.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs JPM's 3.3% | |
| Value | Lower P/E (14.0x vs 17.6x), PEG 0.27 vs 0.97 | |
| Quality / Margins | 30.4% margin vs JPM's 20.4% | |
| Stability / Safety | Beta 0.69 vs JPM's 0.94, lower leverage | |
| Dividends | 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +21.8% vs DOCS's -64.8% | |
| Efficiency (ROA) | 16.5% ROA vs JPM's 1.3%, ROIC 19.8% vs 4.5% |
DOCS vs VEEV vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DOCS vs VEEV vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 434.7x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to JPM's 20.4%. On growth, VEEV holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $645M | $3.3B | $280.3B |
| EBITDAEarnings before interest/tax | $227M | $1.1B | $81.4B |
| Net IncomeAfter-tax profit | $196M | $942M | $57.0B |
| Free Cash FlowCash after capex | $215M | $518M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +89.1% | +75.0% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +28.8% | +25.9% |
| Net MarginNet income ÷ Revenue | +30.4% | +28.4% | +20.4% |
| FCF MarginFCF ÷ Revenue | +33.3% | +15.6% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.1% | +16.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -67.7% | +14.6% | +16.0% |
Valuation Metrics
JPM leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 45% valuation discount to VEEV's 29.3x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs VEEV's 1.61x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $3.7B | $25.9B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $24.6B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | 20.45x | 29.33x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.99x | 17.61x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | 0.39x | 1.61x | 0.90x |
| EV / EBITDAEnterprise value multiple | 16.47x | 20.59x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 5.81x | 8.11x | 3.20x |
| Price / BookPrice ÷ Book value/share | 4.20x | 3.69x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | 18.70x | 8.88x |
Profitability & Efficiency
DOCS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
DOCS delivers a 19.4% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $13 for VEEV. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), DOCS scores 6/9 vs JPM's 5/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +19.4% | +13.4% | +15.9% |
| ROA (TTM)Return on assets | +16.5% | +11.0% | +1.3% |
| ROICReturn on invested capital | +19.8% | +12.9% | +4.5% |
| ROCEReturn on capital employed | +20.7% | +13.8% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.01x | 2.60x |
| Net DebtTotal debt minus cash | -$209M | -$1.3B | $599.0B |
| Cash & Equiv.Liquid assets | $219M | $1.4B | $343.3B |
| Total DebtShort + long-term debt | $10M | $96M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $3,781 for DOCS. Over the past 12 months, JPM leads with a +21.8% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs DOCS's -15.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -53.7% | -27.3% | -0.5% |
| 1-Year ReturnPast 12 months | -64.8% | -43.5% | +21.8% |
| 3-Year ReturnCumulative with dividends | -38.7% | -16.2% | +138.2% |
| 5-Year ReturnCumulative with dividends | -62.2% | -47.5% | +118.2% |
| 10-Year ReturnCumulative with dividends | -62.2% | +367.2% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -15.0% | -5.7% | +33.6% |
Risk & Volatility
Evenly matched — VEEV and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
VEEV is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 0.69x | 0.94x |
| 52-Week HighHighest price in past year | $76.51 | $310.50 | $337.25 |
| 52-Week LowLowest price in past year | $17.16 | $148.05 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +26.2% | +51.4% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 43.8 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 3.9M | 2.3M | 7.0M |
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DOCS as "Hold", VEEV as "Buy", JPM as "Buy". Consensus price targets imply 47.5% upside for VEEV (target: $235) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $29.47 | $235.38 | $339.75 |
| # AnalystsCovering analysts | 23 | 43 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | 0 | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +11.5% | +0.7% | +3.9% |
JPM leads in 3 of 6 categories (Valuation Metrics, Total Returns). DOCS leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.
DOCS vs VEEV vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DOCS or VEEV or JPM a better buy right now?
For growth investors, Veeva Systems Inc.
(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Veeva Systems Inc. (VEEV) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DOCS or VEEV or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Veeva Systems Inc. at 29. 3x. On forward P/E, Doximity, Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus Veeva Systems Inc. 's 0. 97x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — DOCS or VEEV or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: JPM returned +465. 8% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DOCS or VEEV or JPM?
By beta (market sensitivity over 5 years), Veeva Systems Inc.
(VEEV) is the lower-risk stock at 0. 69β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 38% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — DOCS or VEEV or JPM?
By revenue growth (latest reported year), Veeva Systems Inc.
(VEEV) is pulling ahead at 16. 3% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, DOCS leads at 15. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DOCS or VEEV or JPM?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus 20. 4% for JPMorgan Chase & Co. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 26. 0% for JPM. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DOCS or VEEV or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus Veeva Systems Inc. 's 0. 97x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Doximity, Inc. (DOCS) trades at 14. 0x forward P/E versus 17. 6x for Veeva Systems Inc. — 3. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 47. 5% to $235. 38.
08Which pays a better dividend — DOCS or VEEV or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. DOCS, VEEV do not pay a meaningful dividend and should not be held primarily for income.
09Is DOCS or VEEV or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, DOCS: -62. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DOCS and VEEV and JPM?
These companies operate in different sectors (DOCS (Healthcare) and VEEV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DOCS is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while DOCS, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.